New Hampshire residents in Manchester, Nashua, Concord, and communities throughout the Lakes Region, Seacoast, and North Country can now access a clinically reviewed oral minoxidil prescription entirely online. There is no in-person visit required, no video call, and no specialist referral required — just a short intake form reviewed by a licensed nurse practitioner.
All care is provided by a clinician licensed in your state.
Oral minoxidil is a prescription tablet originally developed as a treatment for high blood pressure. Its effect on hair growth was discovered as an unintended but well-documented side effect during cardiovascular use — patients on the drug consistently reported new hair growth in areas of previous thinning or loss. This led researchers to investigate whether low-dose oral minoxidil could be prescribed intentionally for androgenetic alopecia, the most common cause of progressive hair loss in adults.
That investigation produced a substantial body of clinical literature supporting its off-label use. Today, low-dose oral minoxidil is a recognized option in dermatology for both men and women with pattern hair loss. "Off-label" means the medication is used for a purpose beyond its original FDA-approved indication — this is a routine, legal practice when a licensed provider determines the use is clinically appropriate for a given patient.
At the doses used for hair loss — 1.25mg for women and 2.5mg for men — the medication works by extending the active growth phase of hair follicles and improving blood flow to the scalp. Because it is taken orally and absorbed systemically, it reaches follicles across the full scalp rather than only where a topical solution is applied.
Expectations should be realistic. Hair growth is slow. Most patients who respond to treatment begin to notice reduced shedding within the first two to three months. More visible changes in density typically emerge around months four to six. A clearer assessment of overall results usually isn't possible until nine to twelve months of consistent daily use. Individual responses vary considerably, and results are not guaranteed.
Women: 1.25 mg daily
Men: 2.5 mg daily
Dose is determined by your provider based on your individual health profile and history.
The entire process is handled online. Here is what happens at each stage — including when payment is collected and what you can expect after submitting your intake.
| Stage | What Happens |
|---|---|
| Step 1 — Intake | You complete a brief health questionnaire online. No payment information is collected. The form gathers the health history and personal details needed for a clinical review. |
| Step 2 — Review | A licensed nurse practitioner reviews your submission within 24 hours. They evaluate whether oral minoxidil is clinically appropriate for your situation based on what you've provided. |
| Step 3 — Decision | If treatment is appropriate, you receive consent documents and a Stripe payment authorization for the $50 provider fee via email. If treatment is not appropriate, you are notified and no fee is charged. |
| Step 4 — Payment | You review the consent forms, authorize the $50 charge by signing the Stripe authorization, and confirm your pharmacy preference. You are not charged automatically — this step requires your active approval. |
| Step 5 — Prescription | Your prescription is sent electronically to your chosen New Hampshire pharmacy or mail-order service. Medication is billed directly by the pharmacy — separate from the provider fee. |
Low-dose oral minoxidil has a well-studied safety profile. At the doses used for hair loss, it is generally tolerated without significant complications for most patients. That said, side effects are possible and worth understanding before beginning treatment.
The most frequently reported side effect is hypertrichosis — unwanted hair growth in areas beyond the scalp. This includes the face, forearms, or body. It is more common in women and tends to be mild at 1.25mg, but it is worth factoring into your decision. Some patients choose to discontinue treatment because of it.
Fluid retention is another possible effect. At cardiovascular doses, this was clinically significant. At the low doses used for hair loss, it tends to manifest as subtle swelling around the ankles or eyes, if at all. Patients with underlying heart or kidney conditions may warrant more careful evaluation before this medication is considered.
Some patients experience a temporary increase in shedding during the first month or two of treatment. This is a known phase during which the hair follicle transitions growth cycles and does not indicate the medication is failing. It generally resolves on its own.
The intake review is designed to surface any red flags before a prescription is issued. Not every patient who submits an intake will be determined to be a good candidate for this treatment.
Increased hair in areas outside the scalp — face, arms, or body. More common in women. Typically mild at 1.25mg daily doses.
Possible mild swelling, most often around the ankles. Less common at low doses than at cardiovascular doses. More relevant for patients with pre-existing heart or kidney conditions.
A temporary increase in hair shedding during the first four to eight weeks. Generally self-resolving and not a sign of treatment failure.
Occasional dizziness, particularly when standing quickly. Uncommon at low doses but worth noting, especially for patients with low baseline blood pressure.
Clinical appropriateness is determined individually by the reviewing provider. These are the most common patient profiles — not an eligibility list.
Pattern hair loss — whether hairline recession in men or diffuse thinning in women — is the primary indication for low-dose oral minoxidil. Both sexes can be evaluated for this treatment.
Those who have used topical minoxidil and found it ineffective, irritating, or difficult to maintain consistently may find oral administration more practical. A provider can evaluate the clinical rationale.
For many people — especially those outside of Manchester or Nashua where specialist access is more concentrated — scheduling an in-person dermatology appointment involves significant time and travel. This service removes that barrier.